Equities

Mangalam Drugs and Organics Ltd

MANGALAM:NSI

Mangalam Drugs and Organics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)99.95
  • Today's Change0.80 / 0.81%
  • Shares traded18.44k
  • 1 Year change-11.55%
  • Beta1.1636
Data delayed at least 15 minutes, as of Apr 19 2024 10:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mangalam Drugs and Organics Limited is an India-based manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Under the Company's Fight Malaria Program, it supplies anti-malaria APIs worldwide. Its products include API, intermediates and specialty chemicals. Its API products include acyclovir, amodiaquine, artemether, artesunate, atazanavir sulfate, bisoprolol fumarate, chloroquine phosphate, furosemide and dolutegravir sodium. The Company's intermediates products include 4,6-Dichloro-5-Methoxy Pyrimidine; 4,7- dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base, and tenofovir disoproxil base. Its specialty chemicals products include L (+)-menthol; 2,3-dihydrophthalazine-1,4-dione or phthalazine-1,4-dione, and 4-cynoethyl-2-methyl phenol. Its pipeline APIs (under development) include Ganaplacide (IH), Tafenoquine Succinate (IH) and Pretomanid (IH). Its pipeline APIs (developed at research and development) is Bictegravir Na (IH).

  • Revenue in INR (TTM)3.57bn
  • Net income in INR-169.87m
  • Incorporated1972
  • Employees523.00
  • Location
    Mangalam Drugs and Organics Ltd3Rd FloorRupam Building 239, P. D'mello RoadMUMBAI 400001IndiaIND
  • Phone+91 2 222616200
  • Fax+91 2 222619090
  • Websitehttps://www.mangalamdrugs.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Aarey Drugs and Pharmaceuticals Ltd3.48bn42.19m1.31bn0.0028.03--22.870.37551.661.66137.72------------2.78--5.844.173.661.211.52--1.63-----14.963.70-42.38-9.4010.95--
Sotac Pharmaceuticals Ltd579.83m44.96m1.35bn89.0021.868.5322.022.335.585.5860.6914.31----------------30.90--7.75--0.99688.620.4806---20.74--56.17------
Mangalam Drugs and Organics Ltd3.57bn-169.87m1.57bn523.00------0.439-10.74-10.74225.21--------6,834,930.00--3.70--6.5026.3829.07-4.752.87---0.5682-----17.475.91-93.54-42.3211.78--
Krebs Biochemicals And Industries Ltd499.09m-208.21m1.58bn210.00------3.17-9.50-9.5022.86--------2,376,624.00---18.88---29.0486.2811.95-41.72-59.37---3.78-----12.689.0744.55--28.63--
Bal Pharma Ltd3.27bn35.19m1.58bn--46.10--11.690.48372.172.17209.85------------0.1785--0.478244.0243.811.080.1865--1.34--132.388.187.54-54.17-1.5631.090.00
Vaishali Pharma Ltd801.21m58.38m1.76bn--31.78--27.622.195.155.1568.64------------3.32--8.6417.7215.067.293.71--4.37-----8.120.507264.1252.62-4.18--
Data as of Apr 19 2024. Currency figures normalised to Mangalam Drugs and Organics Ltd's reporting currency: Indian Rupee INR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.